AI Article Synopsis
- Implementation of decision aids for prostate cancer treatment is low, with only 35% of patients receiving the aid in a Dutch study, highlighting variations across hospitals (16%-84%)
- Most patients who received the decision aid accessed its features and discussed the summary with their providers, indicating some level of engagement in shared decision-making
- Involving nurses in distributing decision aids improved uptake, but further efforts are needed to increase both the usage and effectiveness of these tools, especially before diagnosis consultations
Article Abstract
Implementation of patient's decision aids in routine clinical care is generally low. This study evaluated uptake and usage of a novel Dutch web-based prostate cancer treatment decision aid within the Prostate Cancer Patient Centered Care trial. From an estimated total patient sample of 1006 patients, 351 received a decision aid (35% implementation rate; hospital ranges 16%-84%). After receipt of the decision aid, most patients accessed the decision aid, utilized most functions, although not completely, and discussed the decision aid summary in a subsequent consultation with their care provider. Including nurses for dissemination of decision aids seemed to positively affect decision aid uptake. Once received, patients seemed able to use the decision aid and engage in shared decision-making as intended; however, decision aid uptake and complete usage of all decision aid components should be further improved. Prior to the diagnosis consultation, handing out of the decision aid should be prepared.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1460458218779110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing stroke disease classification through machine learning models via a novel voting system by feature selection techniques.
PLoS One
January 2025
Institute for Physical Activity and Nutrition, Deakin University, Melbourne, VIC, Australia.
Heart disease remains a leading cause of mortality and morbidity worldwide, necessitating the development of accurate and reliable predictive models to facilitate early detection and intervention. While state of the art work has focused on various machine learning approaches for predicting heart disease, but they could not able to achieve remarkable accuracy. In response to this need, we applied nine machine learning algorithms XGBoost, logistic regression, decision tree, random forest, k-nearest neighbors (KNN), support vector machine (SVM), gaussian naïve bayes (NB gaussian), adaptive boosting, and linear regression to predict heart disease based on a range of physiological indicators.
View Article and Find Full Text PDFUse and limitations of clinical data in the identification and classification of low molecular weight chemicals (LMWCs) as respiratory sensitizers: recommendations for improvement.
Crit Rev Toxicol
January 2025
Syngenta, Bracknell, United Kingdom.
While progress has been made in recent years, there are still no suitable and accepted , or models that can be used to accurately predict whether a chemical substance has the intrinsic property to cause immune-mediated chemical respiratory allergy, typically manifested as allergic asthma or allergic rhinitis which represents a severe health hazard. Regulatory authorities have relied primarily on clinical evidence (case reports, clinical databases, worker exposure studies) to classify substances as respiratory sensitizers, but this evidence can lack a proven immunological mechanism which is necessary to identify substances which can cause life-long sensitization and clinically relevant allergic symptoms in the respiratory tract in an exposed population (such respiratory allergens may be considered as "true" sensitizers, in analogy to the definition of skin sensitization, and in contrast to respiratory irritants). In light of this, the European Center for Ecotoxicology and Toxicology of Chemicals convened a Task Force to evaluate the types of clinical methods and data sources and the implications of relying on such data for regulatory decision making from a scientific perspective.
View Article and Find Full Text PDFBackground: There is a critical need for minimally-invasive robust peripheral markers of neurodegenerative conditions. Peripheral RNA may be a powerful tool for in-depth tracking of biological processes in AD and related disorders. Here, we combine whole-blood microarray data from Alzheimer's Disease Neuroimaging Initiative (ADNI; N=743) and RNA-Seq from Translational Biomarkers in Aging and Dementia (TRIAD; N=77) and Montreal Neurological Institute (MNI; N=33) cohorts to predict cognitive performance across AD spectrum.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Background: Analysis of neuroimaging data based on convolutional neural networks (CNNs) can improve detection of clinically relevant characteristics of patients with Alzheimer's disease (AD). Previously, our group developed a CNN-based approach for detecting AD via magnetic resonance imaging (MRI) scans and for identifying features that are relevant to the decision of the network. In the current study, we aimed to evaluate the potential utility of applying this approach to MRI scans to assist in the identification of individuals at high risk for amyloid positivity to aid in the selection of study samples and case finding for treatment.
View Article and Find Full Text PDFTranstracheal Ultrasound as a Preventive Tool for ETT Related Adverse Events and Malpositioning in the ICU.
J Intensive Care Med
January 2025
The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Introduction: Endotracheal tube (ETT) malpositioning can result in a myriad of complications. Daily chest radiographs (CXR) is the gold standard in monitoring these complications. Point-of-care transtracheal ultrasound (TTUS) is an emerging imaging modality for ETT positioning.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!